88
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Acetylation-dependent regulation of essential iPS-inducing factors: a regulatory crossroad for pluripotency and tumorigenesis

      research-article
      , , , ,
      Cancer Medicine
      Blackwell Publishing Ltd
      Akt, iPS cell, Klf4, Oct4, p300, Sox2

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Induced pluripotent stem (iPS) cells can be generated from somatic cells by coexpression of four transcription factors: Sox2, Oct4, Klf4, and c-Myc. However, the low efficiency in generating iPS cells and the tendency of tumorigenesis hinder the therapeutic applications for iPS cells in treatment of human diseases. To this end, it remains largely unknown how the iPS process is subjected to regulation by upstream signaling pathway(s). Here, we report that Akt regulates the iPS process by modulating posttranslational modifications of these iPS factors in both direct and indirect manners. Specifically, Akt directly phosphorylates Oct4 to modulate the Oct4/Sox2 heterodimer formation. Furthermore, Akt either facilitates the p300-mediated acetylation of Oct4, Sox2, and Klf4, or stabilizes Klf4 by inactivating GSK3, thus indirectly modulating stemness. As tumorigenesis shares possible common features and mechanisms with iPS, our study suggests that Akt inhibition might serve as a cancer therapeutic approach to target cancer stem cells.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

          Glycogen synthase kinase-3 (GSK3) is implicated in the regulation of several physiological processes, including the control of glycogen and protein synthesis by insulin, modulation of the transcription factors AP-1 and CREB, the specification of cell fate in Drosophila and dorsoventral patterning in Xenopus embryos. GSK3 is inhibited by serine phosphorylation in response to insulin or growth factors and in vitro by either MAP kinase-activated protein (MAPKAP) kinase-1 (also known as p90rsk) or p70 ribosomal S6 kinase (p70S6k). Here we show, however, that agents which prevent the activation of both MAPKAP kinase-1 and p70S6k by insulin in vivo do not block the phosphorylation and inhibition of GSK3. Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and we demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC). Like the inhibition of GSK3 (refs 10, 14), the activation of PKB is prevented by inhibitors of phosphatidylinositol (PI) 3-kinase.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reprogramming of human somatic cells to pluripotency with defined factors.

            Pluripotency pertains to the cells of early embryos that can generate all of the tissues in the organism. Embryonic stem cells are embryo-derived cell lines that retain pluripotency and represent invaluable tools for research into the mechanisms of tissue formation. Recently, murine fibroblasts have been reprogrammed directly to pluripotency by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield induced pluripotent stem (iPS) cells. Using these same factors, we have derived iPS cells from fetal, neonatal and adult human primary cells, including dermal fibroblasts isolated from a skin biopsy of a healthy research subject. Human iPS cells resemble embryonic stem cells in morphology and gene expression and in the capacity to form teratomas in immune-deficient mice. These data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Establishment in culture of pluripotential cells from mouse embryos.

                Bookmark

                Author and article information

                Journal
                Cancer Med
                Cancer Med
                cam4
                Cancer Medicine
                Blackwell Publishing Ltd (Oxford, UK )
                2045-7634
                2045-7634
                October 2014
                13 August 2014
                : 3
                : 5
                : 1211-1224
                Affiliations
                Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts
                Author notes
                Hiroyuki Inuzuka, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115. Tel: 1-617-735-2494; Fax: 1-617-735-2480; E-mail: hinuzuka@ 123456bidmc.harvard.edu

                Funding Information This work was supported by grants from the National Institute of Health (H. I., AG041218). P. L. is supported by 5T32HL007893.

                [*]

                These three authors contributed equally to this work.

                Article
                10.1002/cam4.298
                4302671
                25116380
                51ac46a1-2e5e-4754-a70d-80d75d21896b
                © 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 17 March 2014
                : 04 June 2014
                : 10 June 2014
                Categories
                Cancer Biology
                Original Research

                Oncology & Radiotherapy
                akt,ips cell,klf4,oct4,p300,sox2
                Oncology & Radiotherapy
                akt, ips cell, klf4, oct4, p300, sox2

                Comments

                Comment on this article